PubRank

Nature clinical practice. Endocrinology & metabolism (Nat Clin Pract Endocrinol Metab)

Journal PubWeight™ 372.12‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. 2008 4.61
2 Dyslipidemia in type 2 diabetes mellitus. 2009 3.98
3 Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. 2008 3.80
4 Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. 2007 3.25
5 The replication of beta cells in normal physiology, in disease and for therapy. 2007 2.72
6 Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. 2007 2.48
7 Mechanisms of disease: glucocorticoids, their placental metabolism and fetal 'programming' of adult pathophysiology. 2007 2.44
8 The pathogenesis of diabetic nephropathy. 2008 2.34
9 Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. 2006 2.31
10 The prevention of type 2 diabetes. 2008 2.27
11 Mechanisms of macrophage activation in obesity-induced insulin resistance. 2008 2.24
12 Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. 2008 2.13
13 The role of thyroid autoimmunity in fertility and pregnancy. 2008 2.06
14 Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates. 2007 2.03
15 Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. 2007 2.02
16 The role of physical activity in producing and maintaining weight loss. 2007 1.98
17 Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications. 2006 1.88
18 Mechanisms of disease: proatherogenic HDL--an evolving field. 2006 1.83
19 New therapeutic approaches to treat medullary thyroid carcinoma. 2008 1.76
20 Thyroid hormone receptors in brain development and function. 2007 1.72
21 Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease. 2006 1.70
22 Technology insight: In vitro culture of spermatogonial stem cells and their potential therapeutic uses. 2006 1.66
23 Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. 2006 1.63
24 Differentiating between body fat and lean mass-how should we measure obesity? 2008 1.61
25 Biologic actions and therapeutic potential of the proglucagon-derived peptides. 2005 1.56
26 Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. 2007 1.56
27 Mechanisms of disease: the developmental origins of disease and the role of the epigenotype. 2007 1.54
28 How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus? 2008 1.54
29 Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias. 2007 1.51
30 Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. 2006 1.50
31 Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity. 2008 1.49
32 Clinical lessons from the calcium-sensing receptor. 2007 1.48
33 Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. 2007 1.48
34 A comparison of classification schemes for ketosis-prone diabetes. 2007 1.44
35 Generalized arterial calcification of infancy: treatment with bisphosphonates. 2009 1.43
36 Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? 2007 1.42
37 Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. 2008 1.42
38 Gestational diabetes mellitus: postpartum opportunities for the diagnosis and prevention of type 2 diabetes mellitus. 2008 1.42
39 Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. 2007 1.41
40 A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. 2007 1.35
41 Nonalcoholic fatty liver disease: from pathogenesis to patient care. 2007 1.31
42 Therapy Insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression? 2007 1.30
43 Endocrine manifestations of hepatitis C virus infection. 2009 1.30
44 Thyroid-hormone therapy and thyroid cancer: a reassessment. 2005 1.30
45 Does addition of sitagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus? 2007 1.29
46 Therapy insight: management of Graves' disease during pregnancy. 2007 1.27
47 The genetics of the polycystic ovary syndrome. 2007 1.26
48 Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. 2005 1.26
49 Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. 2008 1.22
50 Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. 2008 1.22
Next 50